Compositions and methods for the treatment of severe pain
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain, generalized pain disorders, leukemia, cancer, chronic pain, chemotherapy induced pain, epilepsy, migraine, neuropathic pain, post herpetic neuralgia, neuralgia, pain, drug addiction, detoxification of drugs, Alzheimer's disease, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder.
1. A compound of Formula I:
or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, enantiomer, or stereoisomer thereof, wherein:
R 1 and R 2 each independently represents —H, —CH 3 , —D;
R 3 represents;
R 4 represents
a is 2, 3 or 7;
each b is independently 3, 5 or 6;
e is 1, 2 or 6; and
c and d are each independently H, D, —OH, —OD, C 1 -C 6 -alkyl, —NH 2 or —COCH 3 .
2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , wherein said pharmaceutical composition is formulated to palliatively treat severe pain by administering an effective amount of the pharmaceutical composition to a patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.
4. The pharmaceutical composition of claim 2 , further comprising a molecular conjugate of methadone and carboxylic compounds selected from a group consisting of R-Lipoic acid, eicosapentaenoic acid, docosahexaenoic acid, acetyl cysteine, salsalate and fumaric acid.
5. The pharmaceutical composition of claim 4 , wherein the carboxylic compound is R-Lipoic acid.
6. The pharmaceutical composition of claim 4 , wherein the carboxylic compound is eicosapentaenoic acid.
7. The pharmaceutical composition of claim 4 , wherein the carboxylic compound is docosahexaenoic acid.
8. The pharmaceutical composition of claim 4 , wherein the carboxylic compound is acetyl cysteine.
9. The pharmaceutical composition of claim 4 , wherein the carboxylic compound is salsalate.
10. The pharmaceutical composition of claim 4 , wherein the carboxylic compound is fumaric acid.
11. A method of palliatively treating severe pain, the method comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition of claim 3 .
12. The method of claim 11 , wherein the severe pain is caused by neurologic diseases selected from generalized pain disorders, leukemia, cancer, chronic pain, chemotherapy induced pain, epilepsy, migraine, neuropathic pain, post herpetic neuralgia, neuralgia, drug addiction, detoxification of drugs, Alzheimer's disease, multiple sclerosis, multiple sclerosis, restless legs syndrome, cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis, convulsions, partial seizures or bipolar disorder.